What is this study trying to find out about early breast cancer?

This study is observing how patients with HER2-negative early breast cancer in France use Olaparib treatment. It aims to understand the completion rate of this treatment during regular care. The study is sponsored by AstraZeneca and gathers real-world information to help improve patient management.

Who may be eligible for this early breast cancer clinical trial?

Adults aged 18 years or older diagnosed with HER2-negative early breast cancer who are starting adjuvant Olaparib treatment may be eligible. Both male and female patients can participate. Patients must agree to join the study and not be part of an early access program. Please review eligibility criteria for more details.

Is there any cost to participate in this early breast cancer clinical trial?

Study-related care, including the study treatment and all trial visits, is provided at no cost. However, personal expenses such as travel may vary and are not guaranteed to be covered.

Actively Recruiting

Age: 18Years +

All Genders

ID06856343

REBECCA Real-world Early Breast Cancer Management A French National Multicentric Real-world Study of Early Breast Cancer Patients

Led by AstraZeneca · Updated on 2026-05-26

126

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

This research aims to observe patients with HER2-negative early breast cancer in France who are treated with the drug Olaparib as part of their regular care. The study focuses on understanding how many patients complete the full course of adjuvant Olaparib treatment. It is a national, multicenter, prospective cohort study designed to gather real-world data on this patient group. The study follows patients who begin Olaparib treatment as decided by their doctors. There are no experimental treatments or placebo groups since this is an observational study. Researchers will monitor patients for up to 18 months after they start the Olaparib therapy to gather detailed information about treatment duration and patient characteristics. Participants will be observed throughout their treatment period, with data collected on how long they stay on Olaparib and any relevant medical history or genetic details such as BRCA mutation types. The main outcome measured is the proportion of patients completing the full 18-month treatment. Secondary outcomes include time to treatment discontinuation and variant types. No additional interventions are required, and the study monitors patients progress through their usual clinical visits.

CONDITIONS

Brief Title

REBECCA Real-world Early BrEast CanCer mAnagement

Who Can Participate

Age: 18Years +

All Genders

Eligibility Criteria

You may qualify if you...

Male or female aged 6 18 years
Diagnosed with HER2-negative early breast cancer
About to start adjuvant Olaparib treatment prescribed by their physician
Informed about the study and do not object to participation

You will not qualify if you...

Not consenting to participate
Currently included in the Early Access Program for Olaparib treatment
Objecting to participation in the study or withdrawing consent during the study period (implied by non-consent criteria in source)

Research Team

AstraZeneca Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here